Lumira Ventures
Venture capitalToronto, Ontario · Pre-Seed–Late Stage
Investment thesis
Lumira Ventures invests in biotherapeutic and medical device companies across multiple stages, seeking to generate tangible patient impact through four key objectives: disrupting treatment paradigms for previously untreatable diseases; addressing unmet medical needs in vulnerable populations; advancing therapeutic effectiveness; and reducing overall care costs. The firm leverages a broad network of relationships to support co-investors and management teams throughout the value creation process. Since 2017, the firm has allocated carry to the Lumira Foundation to support community-based healthcare initiatives in areas where it operates and invests, linking investment performance with social impact.
Source: firm website, verified Jul 21, 2026.
What they invest in
from 32 of 51 portfolio companiesMedical Devices ×27Biotech ×24Healthtech ×15Deep Tech ×6Digital Health ×6AI & Machine Learning ×3FemTech ×1
HQs:United States×6Canada×4United Kingdom×1
Investments · 51 tracked
founders shown can be your intro pathXyloCor Therapeutics develops gene therapies for advanced coronary artery disease and cardiac damage. The company's lead program, XC001, targets refractory angina in patients with limited treatment options.
BiotechHealthtechMedical Devices
John Tucker(President and Chief Executive Officer)Ronald Crystal(Co-founder)Todd Rosengart(Co-founder)
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development. The company serves patients with cancer through novel drug candidates advancing in clinical trials.
BiotechDigital HealthMedical DevicesVancouver, CA
François Bénard(MD)Kuo-Shyan Lin(PhD)David Perrin(PhD)
Alveolus Bio develops inhaled biotherapeutics using a proprietary platform to deliver engineered bacteria directly to the lungs for treating chronic lung diseases including idiopathic pulmonary fibrosis, bronchiectasis, and COPD. The company targets patients with fibrotic and inflammatory lung conditions.
BiotechDigital HealthMedical Devices
AmacaThera develops a tunable hydrogel drug-delivery platform for long-acting therapeutic administration across various clinical applications, including pain management, oncology, and post-surgical care. The company licenses its proprietary formulation technology to pharmaceutical partners for product development and commercialization.
BiotechMedical Devices
Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry. The company targets an unmet clinical need where no approved therapeutic options currently exist.
BiotechFemTechHealthtechMedical Devices
Axonis Therapeutics develops medicines targeting KCC2 to restore inhibition in the brain, with a focus on treating neurological disorders including epilepsy and pain. The company translates discoveries from Boston Children's Hospital, Harvard, and Laval University into first-in-class and best-in-class treatments.
BiotechMedical DevicesBoston, US
BardyDx develops the Carnation Ambulatory Monitor (CAM), a lightweight cardiac patch monitor designed for extended-wear ambulatory ECG monitoring that emphasizes P-wave signal clarity. The company serves healthcare professionals and patients requiring continuous arrhythmia detection and diagnosis.
Digital HealthHealthtechMedical Devices
Biotheryx discovers and develops targeted protein degrader drugs designed to treat cancer and inflammatory diseases. The company uses its proprietary PRODEGY platform to create molecular glues and bifunctional degraders, with lead programs in clinical trials for oncology indications including breast cancer and hematologic malignancies.
BiotechMedical DevicesSan Diego, US
Bright Angel Therapeutics develops novel small molecule therapeutics for treating drug-resistant and life-threatening fungal infections using computational drug discovery and proprietary fungal-selective inhibitor technologies. The company is a pre-clinical biotechnology firm targeting invasive fungal infections caused by resistant species including Candida, Cryptococcus, and Aspergillus.
BiotechDeep TechMedical DevicesToronto, CA
COUR develops targeted therapies for autoimmune diseases using an antigen-specific platform technology designed to restore immune tolerance while preserving normal immune function. The company focuses on disease-modifying treatments for immune-mediated conditions.
BiotechHealthtechMedical Devices
Gilead discovers, develops, and delivers innovative therapeutics for people with life-threatening diseases, focusing on virology, oncology, and inflammation across more than 35 countries. The company combines scientific rigor with global partnerships and licensing programs to expand access to medicines worldwide.
BiotechDigital HealthHealthtechMedical DevicesFoster City, US
Damona Pharma develops therapies targeting cognitive deficits by using positive allosteric modulators to restore neural connections and improve brain cell communication.
BiotechHealthtechMedical Devices
Edesa Biotech is a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics to treat inflammatory and immune-related diseases, with a current focus on acute respiratory distress syndrome and other immune dysregulation conditions.
BiotechDeep TechMedical Devices
Endogenex develops the pulsENDO system, an endoscopic medical device that applies pulsed electric field technology to the small intestine to reset metabolic signaling for people with type 2 diabetes. The company, founded in partnership with Mayo Clinic, is currently evaluating the investigational system in clinical trials.
HealthtechMedical Devices
Barham K. Abu Dayyeh(Co-inventor, pulsENDO system)
UCB is a global biopharmaceutical company focused on creating treatments for people living with neurological and autoimmune conditions. The company develops medicines and patient support services to improve outcomes for patients with diseases such as myasthenia gravis and axSpA.
BiotechHealthtech
Exact Imaging develops the ExactVu micro-ultrasound platform, a medical device that enables urologists to perform targeted prostate biopsies with high-resolution real-time visualization. The system combines 29 MHz micro-ultrasound imaging with conventional transducers for comprehensive urological procedures.
HealthtechMedical Devices
Fusion Pharma develops targeted alpha therapeutics for cancer treatment using proprietary linker technology to connect alpha-emitting medical isotopes to cancer-targeting molecules, delivering lethal damage to tumor cells while minimizing toxicity to healthy tissues.
BiotechHealthtechMedical Devices
G1 Therapeutics develops cancer therapies focused on improving patient outcomes and quality of life for people with cancer.
Biotech
Cytek Biosciences develops spectral flow cytometry instruments and reagents for cell analysis in cancer and cell biology research. The company serves research laboratories seeking to perform high-parameter fluorochrome analysis with reduced sample preparation time and cost.
BiotechDeep TechMedical DevicesBellevue, US
Histosonics develops histotripsy technology, a non-invasive ultrasound-based treatment modality for physicians to use in clinical procedures. The company aims to bring this novel therapeutic approach to patients worldwide.
Deep TechHealthtechMedical Devices
Iterion Therapeutics is a clinical-stage biopharmaceutical company developing Tegavivint, a targeted Wnt/β-catenin inhibitor for cancers with Wnt-driven mutations, primarily hepatocellular carcinoma and colorectal cancer. The drug works by blocking β-catenin's oncogenic activity through TBL1 inhibition while minimizing the toxicities associated with upstream Wnt inhibitors.
BiotechMedical Devices
KisoJi Biotechnology discovers and develops antibody therapeutics targeting oncology and other diseases using a proprietary platform based on single domain antibodies and AI-enabled fingerprinting technology. The company enables creation of multi-specific antibodies designed for therapeutic, diagnostic, and vaccine applications.
AI & Machine LearningBiotechMedical Devices
Medexus Pharmaceuticals is an orphan drug and rare disease pharmaceutical company with integrated commercial operations, supply chain, regulatory, and medical affairs infrastructure serving the North American market.
Biotech
Nervonik develops peripheral nerve stimulation systems optimized for high-motion applications with novel biosensing technology. The company targets neuromodulation and medical device markets with improved lead stability, connectivity, and durability for long-term efficacy.
Deep TechHealthtechMedical Devices
OpSens Medical develops sensor-guided medical devices, including fiber optic guidewires and hemodynamic monitoring systems, for use in interventional cardiology procedures.
Digital HealthMedical Devices
Puzzle Medical Devices develops a cardiac support device designed to improve heart and kidney function in heart failure patients through a minimally invasive 4Fr axillary approach, enabling patient mobility during treatment.
HealthtechMedical Devices
Specific Biologics develops Dualase, a genome editing platform for in vivo therapeutic applications. The company is advancing a pipeline of therapies targeting CNS, lung, and liver indications caused by genetic drivers, using proprietary two-site mechanisms for precise DNA sequence removal, repair, and insertion.
BiotechDeep TechMedical Devices
SpectraWave develops imaging and physiology technologies for coronary care, combining deep optical coherence tomography, near-infrared spectroscopy, and wire-free FFR measurements on a single platform to support percutaneous coronary intervention planning in catheterization laboratories.
AI & Machine LearningHealthtechMedical Devices
Thryv Therapeutics is a clinical-stage biotech company developing precision medicine treatments for genetic arrhythmia syndromes and cardiometabolic diseases using selective SGK1 inhibitors. The company focuses on cardiac conditions affecting patients with genetic disorders like Long QT Syndrome.
BiotechHealthtech
Congruence is a drug discovery company using protein dynamics, biophysics, machine learning, and computational chemistry to develop predictive models for disease correction. The company serves pharmaceutical and biotech organizations seeking accelerated and more accurate drug discovery processes.
AI & Machine LearningBiotech
X4 Pharmaceuticals develops medicines for people living with rare immune disorders, including treatments for chronic neutropenia. The company focuses on advancing therapeutic solutions in the rare disease space.
BiotechMedical Devices
Zymeworks develops novel medicines for patients with difficult-to-treat diseases using proprietary platforms and in-house R&D capabilities. The company manages a portfolio of healthcare assets across multiple therapeutic indications.
BiotechDigital HealthMedical Devices
Frequently asked questions
- What stage does Lumira Ventures invest at?
- Lumira Ventures invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does Lumira Ventures focus on?
- Lumira Ventures focuses on Biotech, Medical Devices.
- Where is Lumira Ventures located?
- Lumira Ventures is headquartered in Toronto, Ontario.
Similar investors
B Capital is a venture capital firm managing over $12 billion in assets with a stage-based fund approach. The firm invests across early to late-stage companies in technology, healthcare, and energy & resilience sectors, with 200+ portfolio companies and 9 global offices.
DCVC is a deep tech venture capital firm with over a dozen years of experience backing entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, materials science, robotics, space, and biology.
A European investment firm established in 2016 by former Index Ventures life sciences professionals with over 20 years of experience in drug discovery and therapeutic development for unmet medical needs.
Osage University Partners is a venture capital firm founded in 2009 that invests in breakthrough startups emerging from leading research labs and university innovation ecosystems. The firm focuses on technology (software, hardware, climate tech) and life science (therapeutics, medtech, diagnostics, research tools) companies across all stages from pre-seed through crossover, leveraging partnerships with over 150 universities and research institutions globally.
F Prime Capital is an investment firm composed of scientists, engineers, physicians, operators, and investors who provide real-world expertise to help portfolio companies accelerate their path to scalable growth.